Related Experiment Videos

Effects of gliclazide beyond metabolic control

Antonio Ceriello1

  • 1Department of Pathology and Medicine, Experimental and Clinical, University of Udine, 33100 Udine, Italy. antonio.ceriello@uniud.it

Metabolism: Clinical and Experimental
|April 25, 2006
PubMed

Insights

Hyperglycemia triggers oxygen free radicals, driving diabetic complications. The drug gliclazide shows promise by reducing blood sugar and combating oxidative stress, potentially preventing vascular damage.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Diabetology

Background:

  • Hyperglycemia generates oxygen free radicals, initiating diabetic complications.
  • Superoxide overproduction is a key event in diabetic pathogenesis, leading to nitric oxide and peroxynitrite formation.
  • This oxidative stress causes endothelial dysfunction and inflammation in diabetic blood vessels.

Purpose of the Study:

  • To investigate the role of hyperglycemia-derived oxygen free radicals in diabetic complications.
  • To explore the antioxidative properties of gliclazide beyond its hypoglycemic effects.
  • To assess gliclazide as a potential therapeutic agent for preventing diabetic vascular complications.

Main Methods:

  • Review of recent studies on hyperglycemia, oxidative stress, and diabetic pathogenesis.
  • Analysis of evidence supporting gliclazide's antioxidative mechanisms.
  • Evaluation of clinical and basic data on gliclazide's dual action.

Main Results:

  • Hyperglycemia-induced superoxide overproduction is central to diabetic complication pathways.
  • Gliclazide exhibits antioxidative effects independent of its glucose-lowering ability.
  • Gliclazide restores insulin secretion and inhibits glucose-induced oxidative stress.

Conclusions:

  • Gliclazide's dual action of reducing hyperglycemia and oxidative stress is a promising therapeutic strategy.
  • Targeting oxidative stress alongside hyperglycemia may prevent vascular complications in diabetes.
  • Gliclazide represents a potential therapeutic prospect for managing diabetic vascular disease.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...